会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Diagnosis of neurodegenerative diseases
    • 诊断神经退行性疾病
    • US09028801B2
    • 2015-05-12
    • US11792686
    • 2005-12-07
    • Malcolm Andrew WardJohn CollingeGraham Stuart JacksonEmma McGregorNicola Louise LeedsJames CampbellJules Arthur WestbrookHelen Louise Byers
    • Malcolm Andrew WardJohn CollingeGraham Stuart JacksonEmma McGregorNicola Louise LeedsJames CampbellJules Arthur WestbrookHelen Louise Byers
    • A61B5/145G01N33/48C07K14/805C07K14/75C07K14/705G01N33/68
    • G01N33/6896G01N2800/2828G01N2800/56G01N2800/60
    • The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.
    • 本发明涉及一种诊断样品中vCJD的方法,该方法是从人体受试者获取的有效身体组织的诊断样本中,其与检测样本中的蛋白质的浓度相比较,与对照人受试者相比, 蛋白质是:β-肌动蛋白(SwissProt Acc.P60709),载脂蛋白A-IV前体(SwissProt Acc.Po6727); 由残基162-406组成的触珠蛋白β链(SwissProt Acc.P00738); 血红蛋白β链(SwissProt Acc。编号P02023); 或α-1-抗胰蛋白酶(SwissProt Acc。编号P01009); 或与对照组,正常人受试者的样品,蛋白质是血浆蛋白酶(C1)抑制剂前体(SwissProt Acc.No.P05155))相比,诊断样品中蛋白质的浓度降低。 补充成分1的子成分(SwissProt Acc。No.P09871); 丁酰胆碱酯酶前体(SwissProt Acc.Po6276); 补体成分C4B(SwissProt Acc。No.P01028); lumican(SwissProt Acc。No. P51884); α-纤维蛋白原前体(SwissProt Acc。编号P02671); IGHG4蛋白(Swiss Prot Acc。No.Q8TC63)或免疫球蛋白λ重链。 还公开了其它标记蛋白。
    • 9. 发明申请
    • Diagnosis of Neurodegenerative Diseases
    • 诊断神经退行性疾病
    • US20080213802A1
    • 2008-09-04
    • US11792686
    • 2005-12-07
    • Malcolm Andrew WardJohn CollingeGraham Stuart JacksonEmma McGregorNicola Louise LeedsJames CampbellJules Arthur WestbrookHelen Louise Byers
    • Malcolm Andrew WardJohn CollingeGraham Stuart JacksonEmma McGregorNicola Louise LeedsJames CampbellJules Arthur WestbrookHelen Louise Byers
    • G01N33/53C12Q1/02C12Q1/46
    • G01N33/6896G01N2800/2828G01N2800/56G01N2800/60
    • The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.
    • 本发明涉及一种诊断样品中vCJD的方法,该方法是从人体受试者获取的有效身体组织的诊断样本中,其与检测样本中的蛋白质的浓度相比较,与对照人受试者相比, 蛋白质是:β-肌动蛋白(SwissProt Ace.No.P60709),载脂蛋白A-IV前体(SwissProt Acc.Po6727); 由残基162-406组成的触珠蛋白β链(SwissProt Acc.P00738); 血红蛋白β链(SwissProt Ace。编号P02023); 或α-1-抗胰蛋白酶(SwissProt Ace.Po1009); 或与对照组,正常人受试者的样品,蛋白质是血浆蛋白酶(C1)抑制剂前体(SwissProt Acc.No.P05155))相比,诊断样品中蛋白质的浓度降低。 补充成分1的子成分(SwissProt Acc。No.P09871); 丁酰胆碱酯酶前体(SwissProt Acc.Po6276); 补体成分C4B(SwissProt Acc。No.P01028); lumican(SwissProt Ace。No. P51884); α-纤维蛋白原前体(SwissProt Ace。编号P02671); IGHG4蛋白(Swiss Prot Ace。No.Q8TC63)或免疫球蛋白λ重链。 还公开了其它标记蛋白。
    • 10. 发明授权
    • Method and system for facilitating marketing dialogues
    • 促进营销对话的方法和系统
    • US07389320B2
    • 2008-06-17
    • US11353792
    • 2006-02-14
    • Brian ReistadWilliam D. SnapperAndrew C. PayneJames Campbell
    • Brian ReistadWilliam D. SnapperAndrew C. PayneJames Campbell
    • G06F15/16
    • H04L51/32G06F3/04847G06Q10/06316G06Q30/02G06Q30/0201G06Q30/0235G06Q30/0239G06Q30/0241G06Q30/0255G06Q30/0271H04L51/04H04L51/22
    • A system for facilitating marketing dialogues permits multiple instances of multiple scripts to be active at the same time, where each of these dialogues can be at a different place in its script. The dialogues permit interactive communications between the user of the system (such as a marketer) and the user's customers or other participants. Scripts are created using a graphical user interface, in which shapes corresponding to steps in a script are dragged and dropped into a script. Communications can be over a network, by telephone, by mail, or by other means. Overall data from the execution of the scripts can be monitored using another graphical user interface, allowing results and trends to be observed and corrections made to the marketing program. Information regarding the scripts and variables used by the scripts is maintained in a set of tables in one or more databases. A data dictionary provides an interface for data stored in the databases.
    • 用于促进营销对话的系统允许多个脚本的多个实例在同一时间处于活动状态,其中每个对话可以在其脚本中的不同位置。 对话允许系统的用户(如营销人员)与用户的客户或其他参与者之间的交互式通信。 使用图形用户界面创建脚本,其中将与脚本中的步骤对应的形状拖放到脚本中。 通信可以通过网络,电话,邮件或其他方式。 可以使用另一个图形用户界面来监视来自脚本执行的总体数据,从而允许观察结果和趋势并对营销程序进行更正。 关于脚本使用的脚本和变量的信息在一个或多个数据库的一组表中维护。 数据字典提供了存储在数据库中的数据的接口。